These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 25969567)

  • 1. Effect of Glycemic Regulation on Endocan Levels in Patients With Diabetes: A Preliminary Study.
    Arman Y; Akpinar TS; Kose M; Emet S; Yuruyen G; Akarsu M; Ozcan M; Yegit O; Cakmak R; Altun O; Aydin S; Alibeyoğlu A; Ugurlu B; Akcan T; Tukek T
    Angiology; 2016 Mar; 67(3):239-44. PubMed ID: 25969567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endocan and albuminuria in type 2 diabetes mellitus.
    Cikrikcioglu MA; Erturk Z; Kilic E; Celik K; Ekinci I; Yasin Cetin AI; Ozkan T; Cetin G; Dae SA; Kazancioglu R; Erkoc R
    Ren Fail; 2016 Nov; 38(10):1647-1653. PubMed ID: 27756187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Association Between Endocan Levels and Subclinical Atherosclerosis in Patients With Type 2 Diabetes Mellitus.
    Lv Y; Zhang Y; Shi W; Liu J; Li Y; Zhou Z; He Q; Wei S; Liu J; Quan J
    Am J Med Sci; 2017 May; 353(5):433-438. PubMed ID: 28502328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring potential mediators of the cardiovascular benefit of dulaglutide in type 2 diabetes patients in REWIND.
    Konig M; Riddle MC; Colhoun HM; Branch KR; Atisso CM; Lakshmanan MC; Mody R; Raha S; Gerstein HC
    Cardiovasc Diabetol; 2021 Sep; 20(1):194. PubMed ID: 34563178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of canagliflozin, a sodium glucose cotransporter 2 inhibitor, in type 2 diabetes patients with chronic kidney disease: A randomized open-label prospective trial.
    Takashima H; Yoshida Y; Nagura C; Furukawa T; Tei R; Maruyama T; Maruyama N; Abe M
    Diab Vasc Dis Res; 2018 Sep; 15(5):469-472. PubMed ID: 29923427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study.
    August P; Hardison RM; Hage FG; Marroquin OC; McGill JB; Rosenberg Y; Steffes M; Wall BM; Molitch M;
    Clin J Am Soc Nephrol; 2014 Jan; 9(1):64-71. PubMed ID: 24178969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum endocan levels, carotid intima-media thickness and microalbuminuria in patients with newly diagnosed hypertension.
    Oktar SF; Guney I; Eren SA; Oktar L; Kosar K; Buyukterzi Z; Alkan E; Biyik Z; Erdem SS
    Clin Exp Hypertens; 2019; 41(8):787-794. PubMed ID: 31390906
    [No Abstract]   [Full Text] [Related]  

  • 8. PTPN2 Downregulation Is Associated with Albuminuria and Vitamin D Receptor Deficiency in Type 2 Diabetes Mellitus.
    Zheng L; Zhang W; Li A; Liu Y; Yi B; Nakhoul F; Zhang H
    J Diabetes Res; 2018; 2018():3984797. PubMed ID: 30246029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of glycemic control on microalbuminuria development among type 2 diabetes with high-normal albuminuria.
    Chen WZ; Hung CC; Wen YW; Ning HC; Gau BR; Huang YY
    Ren Fail; 2014 Mar; 36(2):171-5. PubMed ID: 24028605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).
    Kinguchi S; Wakui H; Ito Y; Kondo Y; Azushima K; Osada U; Yamakawa T; Iwamoto T; Yutoh J; Misumi T; Aoki K; Yasuda G; Yoshii T; Yamada T; Ono S; Shibasaki-Kurita T; Hosokawa S; Orime K; Hanaoka M; Sasaki H; Inazumi K; Yamada T; Kobayashi R; Ohki K; Haruhara K; Kobayashi Y; Yamanaka T; Terauchi Y; Tamura K
    Cardiovasc Diabetol; 2019 Aug; 18(1):110. PubMed ID: 31455298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Study of Irisin Hormone Level in Type 2 Diabetic Patients and Patients with Diabetic Nephropathy.
    Shelbaya S; Abu Shady MM; Nasr MS; Bekhet MM; Mageed YA; Abbas M
    Curr Diabetes Rev; 2018; 14(5):481-486. PubMed ID: 28875825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Endocan, Ischemia-Modified Albumin, and hsCRP Levels With Endothelial Dysfunction in Type 2 Diabetes Mellitus.
    Balamir I; Ates I; Topcuoglu C; Turhan T
    Angiology; 2018 Aug; 69(7):609-616. PubMed ID: 29172652
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes.
    Coca SG; Ismail-Beigi F; Haq N; Krumholz HM; Parikh CR
    Arch Intern Med; 2012 May; 172(10):761-9. PubMed ID: 22636820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Annual deterioration of renal function in hypertensive patients with and without diabetes.
    Polonia J; Azevedo A; Monte M; Silva JA; Bertoquini S
    Vasc Health Risk Manag; 2017; 13():231-237. PubMed ID: 28721063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glycemic control and extended hemodialysis survival in patients with diabetes mellitus: comparative results of traditional and time-dependent Cox model analyses.
    Williams ME; Lacson E; Wang W; Lazarus JM; Hakim R
    Clin J Am Soc Nephrol; 2010 Sep; 5(9):1595-601. PubMed ID: 20671217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose co-transporter type 2 inhibitors reduce evening home blood pressure in type 2 diabetes with nephropathy.
    Takenaka T; Kishimoto M; Ohta M; Tomonaga O; Suzuki H
    Diab Vasc Dis Res; 2017 May; 14(3):258-261. PubMed ID: 28467199
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The changes in miR-130b levels in human serum and the correlation with the severity of diabetic nephropathy.
    Lv C; Zhou YH; Wu C; Shao Y; Lu CL; Wang QY
    Diabetes Metab Res Rev; 2015 Oct; 31(7):717-24. PubMed ID: 25952368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of apelin, endoglin and endocan with diabetic peripheral neuropathy in type 2 diabetic patients.
    Bilir B; Ekiz Bilir B; Yilmaz I; Soysal Atile N; Yildirim T; Kara SP; Gumustas SA; Orhan AE; Aydin M
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):892-8. PubMed ID: 27010147
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endocan Serum Levels in Patients with Non-Alcoholic Fatty Liver Disease with or without Type 2 Diabetes Mellitus: A Pilot Study.
    Dallio M; Masarone M; Caprio GG; Di Sarno R; Tuccillo C; Sasso FC; Persico M; Loguercio C; Federico A
    J Gastrointestin Liver Dis; 2017 Sep; 26(3):261-268. PubMed ID: 28922438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pulse pressure does not predict the response of diabetic nephropathy to glucose-lowering therapy.
    Nakhjavani M; Nargesi AA; Heidari B; Ghazizadeh Z; Larry M; Esteghamati A
    Diab Vasc Dis Res; 2015 Mar; 12(2):150-1. PubMed ID: 25525076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.